These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1050 related articles for article (PubMed ID: 14998332)

  • 1. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
    Tabrizi MA; Baraldi PG; Preti D; Romagnoli R; Saponaro G; Baraldi S; Moorman AR; Zaid AN; Varani K; Borea PA
    Bioorg Med Chem; 2008 Mar; 16(5):2419-30. PubMed ID: 18077171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists.
    Kalla RV; Elzein E; Perry T; Li X; Palle V; Varkhedkar V; Gimbel A; Maa T; Zeng D; Zablocki J
    J Med Chem; 2006 Jun; 49(12):3682-92. PubMed ID: 16759111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A₂B adenosine receptor antagonists.
    Baraldi PG; Baraldi S; Saponaro G; Preti D; Romagnoli R; Piccagli L; Cavalli A; Recanatini M; Moorman AR; Zaid AN; Varani K; Borea PA; Tabrizi MA
    J Med Chem; 2012 Jan; 55(2):797-811. PubMed ID: 22148859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists.
    Elzein E; Kalla R; Li X; Perry T; Parkhill E; Palle V; Varkhedkar V; Gimbel A; Zeng D; Lustig D; Leung K; Zablocki J
    Bioorg Med Chem Lett; 2006 Jan; 16(2):302-6. PubMed ID: 16275090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20.
    Gessi S; Varani K; Merighi S; Cattabriga E; Pancaldi C; Szabadkai Y; Rizzuto R; Klotz KN; Leung E; Mac Lennan S; Baraldi PG; Borea PA
    Mol Pharmacol; 2005 Jun; 67(6):2137-47. PubMed ID: 15788741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors.
    Varani K; Gessi S; Merighi S; Vincenzi F; Cattabriga E; Benini A; Klotz KN; Baraldi PG; Tabrizi MA; Lennan SM; Leung E; Borea PA
    Biochem Pharmacol; 2005 Nov; 70(11):1601-12. PubMed ID: 16219300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor.
    Carotti A; Cadavid MI; Centeno NB; Esteve C; Loza MI; Martinez A; Nieto R; Raviña E; Sanz F; Segarra V; Sotelo E; Stefanachi A; Vidal B
    J Med Chem; 2006 Jan; 49(1):282-99. PubMed ID: 16392813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships.
    Fernández F; Caamaño O; Isabel Nieto M; López C; García-Mera X; Stefanachi A; Nicolotti O; Isabel Loza M; Brea J; Esteve C; Segarra V; Vidal B; Carotti A
    Bioorg Med Chem; 2009 May; 17(10):3618-29. PubMed ID: 19398343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships.
    Stefanachi A; Nicolotti O; Leonetti F; Cellamare S; Campagna F; Loza MI; Brea JM; Mazza F; Gavuzzo E; Carotti A
    Bioorg Med Chem; 2008 Nov; 16(22):9780-9. PubMed ID: 18938084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
    Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
    J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor.
    Stefanachi A; Brea JM; Cadavid MI; Centeno NB; Esteve C; Loza MI; Martinez A; Nieto R; Raviña E; Sanz F; Segarra V; Sotelo E; Vidal B; Carotti A
    Bioorg Med Chem; 2008 Mar; 16(6):2852-69. PubMed ID: 18226909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
    J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of spin-labeled probes for adenosine receptors.
    Ilas J; Pecar S; Hockemeyer J; Euler H; Kirfel A; Müller CE
    J Med Chem; 2005 Mar; 48(6):2108-14. PubMed ID: 15771453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Preti D; Zaid AN; Saponaro G; Tabrizi MA; Baraldi S; Romagnoli R; Moorman AR; Varani K; Cosconati S; Di Maro S; Marinelli L; Novellino E; Borea PA
    J Med Chem; 2011 Jul; 54(14):5205-20. PubMed ID: 21675777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.
    Yan L; Müller CE
    J Med Chem; 2004 Feb; 47(4):1031-43. PubMed ID: 14761205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and pharmacological evaluation of novel 1,3,8- and 1,3,7,8-substituted xanthines as adenosine receptor antagonists.
    Rodríguez-Borges JE; García-Mera X; Balo MC; Brea J; Caamaño O; Fernández F; López C; Loza MI; Nieto MI
    Bioorg Med Chem; 2010 Mar; 18(5):2001-9. PubMed ID: 20137957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pharmacological evaluation of novel 1- and 8-substituted-3-furfuryl xanthines as adenosine receptor antagonists.
    Balo MC; Brea J; Caamaño O; Fernández F; García-Mera X; López C; Loza MI; Nieto MI; Rodríguez-Borges JE
    Bioorg Med Chem; 2009 Sep; 17(18):6755-60. PubMed ID: 19682912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in A2B adenosine receptor ligands.
    Kalla RV; Zablocki J; Tabrizi MA; Baraldi PG
    Handb Exp Pharmacol; 2009; (193):99-122. PubMed ID: 19639280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Moorman AR; Gessi S; Merighi S; Varani K; Borea PA
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3607-10. PubMed ID: 15177484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.